Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study.
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Y Li, S Li, P Xiu, and S Wang are employees of Jiangsu Hengrui Pharmaceuticals. The other authors declare no conflicts of interest."
"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Jiangsu Hengrui Pharmaceuticals and Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A). Jiangsu Hengrui Pharmaceuticals participated in study design, data collection, data analysis, data interpretation, and writing of the first draft."
"Registration ClinicalTrials.gov:: NCT04414150"
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025